Search

Your search keyword '"Gladman, D."' showing total 1,187 results
Start Over Author "Gladman, D."
1,187 results on '"Gladman, D."'

1. POS0249 ASSOCIATIONS BETWEEN CLINICAL CHARACTERISTICS AND SCREENING MRI FINDINGS: EXPLORATORY ANALYSIS OF THE ONGOING PHASE 4, MULTICENTER, RANDOMIZED, CONTROLLED STAR STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH PsA WITH MRI-CONFIRMED AXIAL INVOLVEMENT

Author

Baraliakos, X., primary, Bird, P., additional, Deodhar, A., additional, Gladman, D. D., additional, Helliwell, P. S., additional, Poddubnyy, D., additional, Kavanaugh, A., additional, Østergaard, M., additional, Soriano, E. R., additional, Tam, L. S., additional, Chakravarty, S. D., additional, Leibowitz, E., additional, Gong, C., additional, Xu, S., additional, Fuerst, T., additional, Saeed, N., additional, Landewé, R., additional, and Mease, P. J., additional

Published
2024
Full Text
View/download PDF

5. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis

Author

Cortes, A, Maksymowych, WP, Wordsworth, BP, Inman, RD, Danoy, P, Rahman, P, Stone, MA, Corr, M, Gensler, Lianne S, Gladman, D, Morgan, A, Marzo-Ortega, H, Ward, MM, SPARCC, TASC, Learch, TJ, Reveille, JD, Brown, MA, and Weisman, MH

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Genetics, 2.1 Biological and endogenous factors, Aetiology, Musculoskeletal, Adult, Bone Resorption, Cervical Vertebrae, Cyclooxygenase 1, Exons, Female, Genetic Association Studies, Genotype, Haplotypes, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteogenesis, Polymorphism, Single Nucleotide, Radiography, Receptor Activator of Nuclear Factor-kappa B, Severity of Illness Index, Spondylitis, Ankylosing, SPARCC, TASC, Ankylosing spondylitis, genetic association study, x-ray, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo identify genetic associations with severity of radiographic damage in ankylosing spondylitis (AS).MethodWe studied 1537 AS cases of European descent; all fulfilled the modified New York Criteria. Radiographic severity was assessed from digitised lateral radiographs of the cervical and lumbar spine using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). A two-phase genotyping design was used. In phase 1, 498 single nucleotide polymorphisms (SNPs) were genotyped in 688 cases; these were selected to capture >90% of the common haplotypic variation in the exons, exon-intron boundaries, and 5 kb flanking DNA in the 5' and 3' UTR of 74 genes involved in anabolic or catabolic bone pathways. In phase 2, 15 SNPs exhibiting p

Published
2015

6. Breast Cancer in Systemic Lupus Erythematosus

Author

Cloutier, B Tessier, Clarke, AE, Ramsey-Goldman, R, Wang, Y, Foulkes, W, Gordon, C, Hansen, JE, Yelin, E, Urowitz, MB, Gladman, D, Fortin, PR, Wallace, DJ, Petri, M, Manzi, S, Ginzler, EM, Labrecque, J, Edworthy, S, Dooley, MA, Senécal, JL, Peschken, CA, Bae, SC, Isenberg, D, Rahman, A, Ruiz-Irastorza, G, Hanly, JG, Jacobsen, S, Nived, O, Witte, T, Criswell, LA, Barr, SG, Dreyer, L, Sturfelt, G, and Bernatsky, S

Subjects
Clinical Research, Breast Cancer, Cancer, Lupus, Autoimmune Disease, Adult, Aged, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Cohort Studies, Disease Susceptibility, Female, Humans, Logistic Models, Lupus Erythematosus, Systemic, Middle Aged, Multivariate Analysis, Odds Ratio, Risk Factors, Breast cancer, Systemic lupus erythematosus, Histopathology, Epidemiology, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

ObjectiveEvidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries.MethodsInformation on age, SLE duration, cancer date, and histology was available. We analyzed information on histological type and performed multivariate logistic regression analyses of histological types according to age, SLE duration, and calendar year.ResultsWe studied 180 breast cancers in the SLE cohort. Of the 155 cases with histology information, 11 were referred to simply as 'carcinoma not otherwise specified'. In the remaining 144 breast cancers, the most common histological type was ductal carcinoma (n = 95; 66%) followed by lobular adenocarcinoma (n = 11; 8%), 15 cancers were of mixed histology, and the remaining ones were special types. In our regression analyses, the independent risk factors for lobular versus ductal carcinoma was age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.01-1.14] and for the 'special' subtypes it was age (OR 1.06, 95% CI 1.01-1.10) and SLE duration (OR 1.05, 95% CI 1.00-1.11).ConclusionsGenerally, up to 80% of breast cancers are ductal carcinomas. Though our results are not definitive, in the breast cancers that occur in SLE, there may be a slight decrease in the ductal histological type. In our analyses, age and SLE duration were independent predictors of histological status.

Published
2013

12. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR

Author

Coates, L., primary, Landewé, R. B. M., additional, Mcinnes, I., additional, Mease, P. J., additional, Ritchlin, C. T., additional, Tanaka, Y., additional, Asahina, A., additional, Behrens, F., additional, Gladman, D. D., additional, Gossec, L., additional, Gottlieb, A. B., additional, Warren, R. B., additional, Ink, B., additional, Bajracharya, R., additional, Coarse, J., additional, and Merola, J. F., additional

Published
2023
Full Text
View/download PDF

13. AB1093 LONG-TERM IMPROVEMENT IN INDIVIDUAL ACR RESPONSE CRITERIA AND RESIDUAL DISEASE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST HOC ANALYSIS OF A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Author

Nash, P., primary, Mcinnes, I., additional, Shawi, M., additional, Nantel, F., additional, Kollmeier, A., additional, Rampakakis, E., additional, Soriano, E., additional, Gladman, D. D., additional, and Deodhar, A., additional

Published
2023
Full Text
View/download PDF

16. AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Author

Gladman, D. D., primary, Starr, M., additional, Ranza, R., additional, Bravo Perdomo, A. M., additional, Strauss, M., additional, Shawi, M., additional, Han, C., additional, Rampakakis, E., additional, Andrew Östör, A., additional, and Mease, P. J., additional

Published
2023
Full Text
View/download PDF

17. POS0590-HPR IDENTIFICATION OF RESPONDER AND DISEASE ACTIVITY THRESHOLDS FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) QUESTIONNAIRE USING POOLED DATA FROM TWO PHASE 3 TRIALS OF BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS

Author

Gossec, L., primary, Coates, L., additional, Orbai, A. M., additional, De Wit, M., additional, Pelligra, C., additional, Lambert, J., additional, Ciaravino, V., additional, Ink, B., additional, Taieb, V., additional, and Gladman, D. D., additional

Published
2023
Full Text
View/download PDF

23. POS1037 EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS

Author

Mease, P. J., primary, Helliwell, P., additional, Gladman, D. D., additional, Poddubnyy, D., additional, Baraliakos, X., additional, Chakravarty, S. D., additional, Kollmeier, A., additional, Xu, X. L., additional, Sheng, S., additional, Xu, S., additional, Shawi, M., additional, Van der Heijde, D., additional, and Deodhar, A., additional

Published
2022
Full Text
View/download PDF

26. AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

Author

Curtis, J., primary, McInnes, I., additional, Rahman, P., additional, Gladman, D. D., additional, Yang, F., additional, Peterson, S., additional, Kollmeier, A., additional, Shiff, N., additional, Han, C., additional, Shawi, M., additional, Tillett, W., additional, and Mease, P. J., additional

Published
2022
Full Text
View/download PDF

27. AB0888 Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

Author

Curtis, J., primary, Mcinnes, I., additional, Rahman, P., additional, Gladman, D. D., additional, Yang, F., additional, Peterson, S., additional, Kollmeier, A., additional, Shiff, N., additional, Han, C., additional, Shawi, M., additional, Tillett, W., additional, and Mease, P. J., additional

Published
2022
Full Text
View/download PDF

31. OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY

Author

Merola, J. F., primary, McInnes, I., additional, Ritchlin, C. T., additional, Mease, P. J., additional, Landewé, R. B. M., additional, Asahina, A., additional, Tanaka, Y., additional, Warren, R. B., additional, Gossec, L., additional, Gladman, D. D., additional, Behrens, F., additional, Ink, B., additional, Assudani, D., additional, Bajracharya, R., additional, Coarse, J., additional, and Coates, L., additional

Published
2022
Full Text
View/download PDF

35. OP0027 ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB

Author

Kristensen, L. E., primary, Strober, B., additional, Poddubnyy, D., additional, Leung, Y. Y., additional, Jo, H., additional, Kwok, K., additional, Vranic, I., additional, Fleishaker, D., additional, Fallon, L., additional, Yndestad, A., additional, and Gladman, D. D., additional

Published
2022
Full Text
View/download PDF

36. AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial

Author

Gladman, D. D., primary, Mease, P. J., additional, Bird, P., additional, Soriano, E., additional, Chakravarty, S. D., additional, Shawi, M., additional, Xu, S., additional, Quinn, S., additional, Gong, C., additional, Leibowitz, E., additional, Tam, L. S., additional, Helliwell, P., additional, Kavanaugh, A., additional, Deodhar, A., additional, Østergaard, M., additional, and Baraliakos, X., additional

Published
2022
Full Text
View/download PDF

37. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Author

Clowse, Megan E. B., Wallace, Daniel J., Furie, Richard A., Petri, Michelle A., Pike, Marilyn C., Leszczyński, Piotr, Neuwelt, C. Michael, Hobbs, Kathryn, Keiserman, Mauro, Duca, Liliana, Kalunian, Kenneth C., Galateanu, Catrinel, Bongardt, Sabine, Stach, Christian, Beaudot, Carolyn, Kilgallen, Brian, Gordon, Caroline, Batalov, A., Bojinca, M., Djerassi, R., Duca, L., Horak, P., Kolarov, Z., Milasiene, R., Monova, D., Otsa, K., Pileckyte, M., Popova, T., Radulescu, F., Rashkov, R., Rednic, S., Repin, M., Stoilov, R., Tegzova, D., Vezikova, N., Vitek, P., Zainea, C., East, Far, Baek, H., Chen, Y., Chiu, Y., Cho, C., Chou, C., Choe, J., Huang, C., Kang, Y., Kang, S., Lai, N., Lee, S., Park, W., Shim, S., Suh, C., Yoo, W., Armengol, H. Avila, Zapata, F. Avila, Santiago, M. Barreto, Cavalcanti, F., Chahade, W., Costallat, L., Keiserman, M., Alcala, J. Orozco, Remus, C. Ramos, Roimicher, L., AbuShakra, M., Agarwal, V., AgmonLevin, N., Kadel, J., Levy, Y., Mevorach, D., Paran, D., Reitblat, T., Rosner, I., Shobha, V., Sthoeger, Z., Zisman, D., Ayesu, K., Berney, S., Box, J., Busch, H., Buyon, J., Carter, J., Chi, J., Clowse, M., Collins, R., Dao, K., Diab, I., Dikranian, A., ElShahawy, M., Gaylis, N., Grossman, J., Halpert, E., Huff, J., Jarjour, W., Kao, A., Katz, R., Kennedy, A., Khan, M., Kivitz, A., Kohen, M., LawrenceFord, T., Lawson, J., Levesque, M., Lowenstein, M., Majjhoo, A., Mcarthur, R., McLain, D., Merrill, J., Murillo, A., Neucks, S., Niemer, G., Noaiseh, G., Parker, C., Pantojas, C., Pattanaik, D., Petri, M., Pickrell, P., Reveille, J., RomanMiranda, A., Rothfield, N., Sankoorikal, A., Sayers, M., Singhal, A., Snyder, A., Striebich, C., Vo, Q., von Feldt, J., Wallace, D., Wasko, M., Young, C., Adelstein, S., Hall, S., Littlejohn, G., Nicholls, D., Suranyi, M., Amoura, Z., Bannert, B., Behrens, F., Perez, L.Carreno, Chakravarty, K., Gonzales, F. Diaz, Davies, K., Doria, A., Emery, P., FernándezNebro, A., Govoni, M., Hachulla, E., Hellmich, B., Houssiau, F., Malaise, M., Margaux, J., Maugars, Y., MuñozFernández, S., Navarro, F., OrdiRos, J., Pellerito, R., PenaSagredo, J., Roussou, E., Schmidt, R. E., UcarAngulo, E., Viallard, JF., Westhovens, R., Worm, M., Yee, C. S., Nayiager, S., Reuter, H., Spargo, C., Bazela, B., Brzosko, M., Chudzik, D., Gasztonyi, B., Geher, P., Ionescu, R., Jeka, S., Kemeny, L., Kiss, E., Kotyla, P., Kovacs, L., Kovalenko, V., Kucharz, E., Kwiatkowska, B., Leszczynski, P., Levchenko, E., Lysenko, G., Majdan, M., Mihailov, C., Nalotov, S., Nedelciu, M., Pavel, M., Raskina, T., Rebrov, B., Rezus, E., Semen, T., Smakotina, S., Stanislavchuk, M., Stanislav, M., Szombati, I., Szucs, G., Udrea, G., Zajdel, J., ZonGiebel, A., Bonfiglioli, R., Bustamante, R., Klumb, E., Ramirez, G. Medrano, Neiva, C., Olguin, M., Gonzaga, J.Reyes, Scotton, A., Ayala, S. Sicsik, Ximenes, A., Sharma, R., Srikantiah, C., Aelion, J., Aranow, C., Baker, M., Chadha, A., Chao, J., Chatham, W., Chow, A., Clay, C., CohenGadol, S., Conaway, D., Denburg, J., Escalante, A., Espinoza, L., Fiechtner, J., Fortin, I., Fraser, A., Furie, R., Gladman, D., Goddard, D., Goldberg, M., GonzalezRivera, R., Gorman, J., Griffin, R., Haaland, D., Halter, D., Hemaiden, A., Hobbs, K., Joshi, V., Lim, S., Kalunian, K., Karpouzas, G., Khraishi, M., Lafyatis, R., Lee, S., Lidman, R., Lue, C., Mohan, M., Mease, P., Mehta, C., Mizutani, W., Nami, A., Nascimento, J., Neuwelt, C., Pappas, J., Pope, J., Porges, A., Roane, G., Rosenberg, D., Ross, S., Saadeh, C., Scoville, C., Sherrer, Y., Solomon, M., Surbeck, W., Valenzuela, G., Waller, P., Alten, R., Baerwald, C., Bienvenu, B., Bombardieri, S., Braun, J., Dival, L., Espinosa, G., Fernandez, I. Figueroa, GomezReino, J., Gordon, C., Hiepe, F., Hopkinson, N., Isenberg, D., Jacobi, A., Jorgensen, C., Guern, V. Le, Paul, C., PegoReigosa, J. M., Heredia, J. Rodriguez, RubbertRoth, A., Sabbadini, M., Schroeder, J., Schwarting, A., Spieler, W., Valesini, G., Wollenhaupt, J., Mendoza, A. Zea, and Zouboulis, C.

Published
2017
Full Text
View/download PDF

39. Efficacité de l’ixékizumab sur la douleur rachidienne, l’activité de la maladie et la qualité de vie chez des patients atteints de rhumatisme psoriasique présentant des symptômes évocateurs d’une atteinte axiale

Author

Deodhar, A., primary, Gladman, D., additional, Bolce, R., additional, Sandoval, D., additional, Park, S.Y., additional, Liu-Leage, S., additional, Nash, P., additional, Poddubnyy, D., additional, and Combe, B., additional

Published
2021
Full Text
View/download PDF

40. Efficacité d’upadacitinib chez des patients atteints de rhumatisme psoriasique actif ayant un nombre d’articulations gonflées élevé ou faible : analyse de sous-groupes de 2 études de phase 3 (SELECT-PsA 1 et SELECT-PsA 2)

Author

Gossec, L., primary, Gladman, D., additional, McDearmon-Blondell, E., additional, Sewerin, P., additional, Ritchlin, C., additional, Feng, D., additional, Lertratanakul, A., additional, Ranza, R., additional, Tam, L.S., additional, Marchesoni, A., additional, Coates, L., additional, and Nash, P., additional

Published
2021
Full Text
View/download PDF

48. AB0550 EFFICACY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND A LOW OR HIGH SWOLLEN JOINT COUNT: A SUBGROUP ANALYSIS OF 2 PHASE 3 STUDIES (SELECT-PsA 1 AND SELECT-PsA 2)

Author

Gossec, L., primary, Gladman, D. D., additional, Mcdearmon-Blondell, E., additional, Sewerin, P., additional, Ritchlin, C. T., additional, Feng, D., additional, Lertratanakul, A., additional, Ranza, R., additional, Tam, L. S., additional, Marchesoni, A., additional, Coates, L. C., additional, and Nash, P., additional

Published
2021
Full Text
View/download PDF

49. OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021

Author

Coates, L. C., primary, Soriano, E., additional, Corp, N., additional, Bertheussen, H., additional, Callis-Duffin, K., additional, Barbosa Campanholo, C., additional, Chau, J., additional, Eder, L., additional, Fernandez, D., additional, Fitzgerald, O., additional, Garg, A., additional, Gladman, D. D., additional, Goel, N., additional, Grieb, S., additional, Helliwell, P., additional, Husni, M. E., additional, Jadon, D., additional, Katz, A., additional, Laheru, D., additional, Latella, J., additional, Leung, Y. Y., additional, Lindsay, C., additional, Lubrano, E., additional, Mazzuoccolo, L., additional, Mcdonald, R., additional, Mease, P. J., additional, O’sullivan, D., additional, Ogdie, A., additional, Olsder, W., additional, Schick, L., additional, Steinkoenig, I., additional, De Wit, M., additional, Van der Windt, D., additional, and Kavanaugh, A., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results